Microbial Spectrum of Blood and Body Cultures in Febrile Episodes of Children Under Chemotherapy for Treatment of Malignant Diseases

Göbel, Verena; Jürgens, H.; Thomas, Lutz; Schwamborn, D.; Rosin, Heinrich; Göbel, U.

doi:10.3109/08880018709141244

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They were compared to 135 febrile infections in 1980/81 (HSCT 2; ONC 133) [9]. In 1980/81 the median age was 9.4 years (range 0.5-27 years) and 8,4 years (range 0.5-21.5 years) in 2000.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

TRENDS IN INFECTIONS IN CHILDREN WITH MALIGNANT DISEASE IN 2000: Comparison of Data of 1980/81

Schneider

Janßen

et al. 2007

Pediatric Hematology and Oncology

Self Cite

View full text Add to dashboard Cite

Children with cancer have an overall chance of survival of 70-80%. Despite significant advances in supportive care during the last years, infections remain a major cause of therapy-associated morbidity and death. Between January and December 2000, oncology patients (ONC) treated on a pediatric oncology ward after chemotherapy (n = 109), loco-regional thermochemotherapy (n = 13), or hematopoietic stem cell (HSCT) transplantation (n = 35) suffered a total of 249 febrile infectious complications (HSCT 40/ONC 209). These episodes were analyzed retrospectively and compared with 125 ONC patients with 133 febrile infections in 1980/81. The relative incidence of fever of unknown origin (FUO) decreased from 1980/81 to 2000 (p <.001). The frequency of bloodstream infections (BSI) in febrile episodes was comparable in both periods with 37% (50/135) in 1980 and 29% (72/249) in 2000. In both periods, gram-positive bacteria were the most frequent organisms, whereas gram-negative organisms were detected in approximately 20% of BSI. In 1980/81 microbiologically (MDI) or clinically documented infections (CDI) were not detected, whereas in 2000 27% of all infectious were MDI/CDI. During the last 20 years, improved diagnostic tools have resulted in an increased detection rate of infectious agents causing febrile episodes in pediatric cancer patients. The comparison of the two observation periods did not reveal a change in the microbiologic spectrum. Despite the fact that in 2000 more patients were treated with intensified chemotherapy because of relapse, infection-related mortality was unchanged compared to 1980/81. This observation may indicate a sufficient preemptive antibacterial therapy followed by better diagnostic tools and goal-oriented treatment.

show abstract

“…They were compared to 135 febrile infections in 1980/81 (HSCT 2; ONC 133) [9]. In 1980/81 the median age was 9.4 years (range 0.5-27 years) and 8,4 years (range 0.5-21.5 years) in 2000.…”

Section: Resultsmentioning

confidence: 99%

“…This cohort was compared to patients treated in 1980/81 [9]. Patients treated for primary disease were distinguished from relapse patients and patients receiving special treatment modalities such as loco-regional thermochemotherapy or HSCT.…”

Section: Methodsmentioning

confidence: 99%

TRENDS IN INFECTIONS IN CHILDREN WITH MALIGNANT DISEASE IN 2000: Comparison of Data of 1980/81

Schneider

Janßen

et al. 2007

Pediatric Hematology and Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…in addition. Since pseudomonal infections did not appear to have been a major problem in the past [10], cefotaxim/oxacillin (150 mg/kg/day i.v. t.i.d.)…”

Section: Supportive Therapymentioning

confidence: 99%

Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care

Lex

Körholz

Kohlmüller

et al. 2001

Support Care Cancer

View full text Add to dashboard Cite

Infections still remain a major cause of therapy-associated morbidity and death in patients with malignant diseases. To further lower the risk of serious and long-lasting infections by additional supportive measures, detailed information on the frequency and characteristic features of infections is needed. Therefore, patient data from 112 children with acute lymphoblastic leukemia and T-cell lymphoma who were treated according to the COALL-05-92 protocol in our department were analyzed for differences in the frequency and origin of febrile episodes in relation to age, immunological type of leukemia, treatment in group assessed as being at high or low risk of relapse, actual occurrence of relapse, and course of chemotherapy. At the time of diagnosis, low-risk patients more commonly presented with febrile episodes than high-risk patients. In total, patients developed a fever in 313 (24%) of 1,307 evaluated chemotherapy cycles. Febrile episodes were associated with microbiologically or clinically documented infections in 60% of all cases, while in 40% the fever was of unknown origin. Gram-positive pathogens had a markedly higher incidence than gram-negative or fungal ones. The incidence of febrile episodes during therapy appeared to be correlated with certain chemotherapeutic drug combinations. The highest rate was found after high-dose cytarabine and asparaginase causing a long period of leukopenia. However, after other chemotherapy courses with a similar duration of leukopenia the incidence of febrile episodes was significantly lower, suggesting that specific interactions of different chemotherapeutic agents with the immune response might be an important factor in development of infections. Individual factors might also account for an increased incidence of infections, since the number of high-risk patients with recurrent infections was significantly higher than expected on the basis of statistical evaluation. In conclusion, our findings suggest that the risk of infections during chemotherapy may not only be influenced by leukopenia, but that drug-specific effects of the various chemotherapeutic agents and individual factors may also be important contributory factors. These observations must be further expanded in prospective studies so that new tailored supportive care protocols can be elaborated.

show abstract

Outpatient treatment with ceftriaxone alone or incombination with teicoplanin in febrile neutropenic children and adolescentswith cancer

Göbel

Jürgens

1997

The Journal of Pediatrics

View full text Add to dashboard Cite

Microbial Spectrum of Blood and Body Cultures in Febrile Episodes of Children Under Chemotherapy for Treatment of Malignant Diseases

Cited by 4 publications

References 8 publications

TRENDS IN INFECTIONS IN CHILDREN WITH MALIGNANT DISEASE IN 2000: Comparison of Data of 1980/81

TRENDS IN INFECTIONS IN CHILDREN WITH MALIGNANT DISEASE IN 2000: Comparison of Data of 1980/81

Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care

Outpatient treatment with ceftriaxone alone or incombination with teicoplanin in febrile neutropenic children and adolescentswith cancer

Contact Info

Product

Resources

About